Loncar Biotech ETFs invest in innovators. Hear straight from CEOs about the companies our ETFs support.

Watch Videos

Zai Lab — CHNA

We believe with China’s talent pool, with China’s development of the whole biotech ecosystem, China is going to be the future source of innovation for the global life sciences industry." − Samantha Du, Ph.D. Chairman & CEO, Zai Lab

Cellectis — CNCR

Gene editing is a paradigm shift in the field of cell therapy, immuno-oncology, and medicine in general and that’s where Cellectis is trying to make the point." − André Choulika Chairman & CEO, CEllectis

Adaptimmune — CNCR

I don’t think anything could be more exciting than trying to have a major effect on cancer patients. It’s a privilege, to be honest, to be involved in such an exciting field." − James Noble CEO, Adaptimmune
CNCR ETF Holdings | CHNA ETF Holdings

Opinions expressed are those of the author or Funds and are subject to change, are not intended to be a forecast of future events, a guarantee of future results, nor investment advice.